SS Innovations International, Inc. announced on May 27, 2025, that its SSi Mantra surgical robotic system has been utilized to successfully perform over 4,000 robotic surgeries. These procedures span more than one hundred types of surgeries and have been completed without any reported complications, injuries, or mortalities.
This milestone includes approximately 215 cardiac surgical procedures, with six of these successfully performed via telesurgery across India using the SSi Mantra 3 system. The growing number of procedures reflects the system's quality, differentiated features, and ease of use.
The SSi Mantra systems are currently cleared to market in seven countries. SS Innovations is actively pursuing entry into the United States and European Union markets, with anticipated EU CE Mark approval by late 2025 and U.S. Food and Drug Administration decision by the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.